Somaxon Pharmaceuticals Incorporated - symbol SOMX - reported that it recently had a meeting with the FDA, who provided clinical and regulatory guidance relating to the over-the-counter development program for Silenor. Somaxon believes that Silenor’s characteristics, including its lack of